This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synergy Pharmaceuticals And Fox Chase Cancer Center Presentation At 2011 ACG Meeting Highlights Potential Of GC-C Agonists To Delay Progression Of Colitis Into Colon Cancer

Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011 annual scientific meeting of the American College of Gastroenterology highlights the potential use of guanylate cyclase-C agonists to delay progression of colitis into colon cancer. Poster P409 was selected as an “ACG Presidential Award Winning Poster”, a recognition given to the most highly ranked abstracts selected for poster sessions in each category. The work reported in poster P409 was a collaborative effort between Synergy scientists and the scientists from Fox Chase Cancer Center, Philadelphia, Drs. Margie Clapper, Wen-Chi Chang and Harry Cooper.

It is well known that patients with both ulcerative colitis (UC) and Crohn’s disease (CD) are at an increased risk of developing colorectal cancer (CRC). A contributing factor to this increased risk appears to be persistent inflammation of the colon.

“We believe that the therapeutic application of GC-C agonists to ameliorate GI inflammation has the potential to delay progression into colon cancer, providing an innovative approach to the treatment of GI inflammatory diseases and prevention of colon cancer,” said Dr. Kunwar Shailubhai, Chief Scientific Officer of Synergy Pharmaceuticals. “Our continued research efforts are focused on exploring GC-C agonists as orally safe drugs to treat GI inflammation and also control its progression to colon cancer.”

These findings represent a significant breakthrough in the clinical care of patients with inflammatory bowel disease, according to Dr. Margie Clapper, Co-Leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center. Intervention with GC-C agonists early in the disease process is expected to block the formation of colon tumors as well as circumvent the need for hundreds of biopsies and, in some cases, major surgery.

The date and time for the presentation are:

Monday October 31, 10:30 am to 4:30 pm

Poster P409: Guanylate Cyclase C Agonists as a New Class of Drug Candidates to Delay Progression of Colitis to Colonic Tumors in Apc Min/+ Mice.

Kunwar Shailubhai 1,2 , Wen-Chi Chang 3 , Shet Masih 2 , Harry S. Cooper 3 , Margie L. Clapper

1 Synergy Pharmaceuticals, Doylestown, PA, 2 Institute of Hepatitis Virus Research, Doylestown, PA, and 3 Fox Chase Cancer Center, Philadelphia, PA, USA.

About Ulcerative Colitis

More than 500,000 Americans are afflicted with ulcerative colitis, a type of IBD that causes chronic inflammation of the colon. Along with Crohn's disease, the other major form of IBD, ulcerative colitis is painful and debilitating, and can lead to other serious and life-threatening complications such as increased incidence of colon cancer. There is currently no medical cure for ulcerative colitis. A considerable medical need exists for the control and treatment of ulcerative colitis.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs